CG-101 Eye Drops in the Treatment of Dry Eye Syndrome

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

May 22, 2025

Study Completion Date

May 22, 2025

Conditions
Dry Eye
Interventions
DRUG

CG101 high dose + artificial tear

Patient in this group received high dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive placebo CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.

DRUG

CG101 low dose + artificial tear

Patient in this group received low dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive high dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.

DRUG

placebo + artificial tear

Patient in this group received placebo dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive low dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.

Trial Locations (1)

20031

RECRUITING

Eye & ENT hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Eye & ENT Hospital of Fudan University

OTHER